Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
ADC Therapeutics Analyst Ratings and Price Targets | NYSE:ADCT | Benzinga
ADC Therapeutics SA has a consensus price target of $5.71 based on the ratings of 10 analysts. The high is $8 issued by RBC Capital on May 15, 2025. The low is $2 issued by Morgan Stanley on July 11, 2023. The 3 most-recent analyst ratings were released by RBC Capital, Guggenheim, and HC Wainwright & Co. on May 15, 2025, March 31, 2025, and March 31, 2025, respectively. With an average price target of $7.67 between RBC Capital, Guggenheim, and HC Wainwright & Co., there's an implied 298.27% upside for ADC Therapeutics SA from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Guggenheim
HC Wainwright & Co.
Stephens & Co.
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for ADC Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2025 | Buy Now | 315.58% | RBC Capital | Gregory Renza56% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/31/2025 | Buy Now | 263.64% | Guggenheim | Michael Schmidt58% | $10 → $7 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 315.58% | HC Wainwright & Co. | Robert Burns44% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt37% | — | Reiterates | Overweight → Overweight | Get Alert |
| 02/24/2025 | Buy Now | 315.58% | Stephens & Co. | Sudan Loganathan14% | $6 → $8 | Maintains | Overweight | Get Alert |
| 01/06/2025 | Buy Now | 315.58% | HC Wainwright & Co. | Robert Burns44% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 419.48% | Guggenheim | Michael Schmidt58% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns44% | — | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 211.69% | Stephens & Co. | Sudan Loganathan14% | → $6 | Initiates | → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 315.58% | HC Wainwright & Co. | Robert Burns44% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 315.58% | RBC Capital | Gregory Renza56% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/30/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt37% | — | Initiates | → Overweight | Get Alert |
| 05/07/2024 | Buy Now | 315.58% | HC Wainwright & Co. | Robert Burns44% | $9 → $8 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 367.53% | HC Wainwright & Co. | Robert Burns44% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | — | Guggenheim | Michael Schmidt58% | — | Reiterates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 471.43% | Guggenheim | Michael Schmidt58% | → $11 | Initiates | → Buy | Get Alert |
| 03/14/2024 | Buy Now | 315.58% | RBC Capital | Gregory Renza56% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 367.53% | HC Wainwright & Co. | Robert Burns44% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | 315.58% | RBC Capital | Gregory Renza56% | $6 → $8 | Maintains | Outperform | Get Alert |
| 02/20/2024 | Buy Now | 367.53% | HC Wainwright & Co. | Robert Burns44% | $3 → $9 | Maintains | Buy | Get Alert |
| 11/20/2023 | Buy Now | 55.84% | HC Wainwright & Co. | Robert Burns44% | $12 → $3 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | — | TD Cowen | Boris Peaker48% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/08/2023 | Buy Now | 211.69% | RBC Capital | Gregory Renza56% | $7 → $6 | Maintains | Outperform | Get Alert |
| 09/19/2023 | Buy Now | 523.38% | HC Wainwright & Co. | Robert Burns44% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 315.58% | RBC Capital | Gregory Renza56% | $9 → $8 | Maintains | Outperform | Get Alert |
| 08/10/2023 | Buy Now | — | JP Morgan | Brian Cheng49% | — | Upgrade | Underweight → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 367.53% | RBC Capital | Gregory Renza56% | $10 → $9 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 523.38% | HC Wainwright & Co. | Robert Burns44% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 3.9% | Morgan Stanley | Jeffrey Hung53% | $5 → $2 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/20/2023 | Buy Now | 523.38% | HC Wainwright & Co. | Robert Burns44% | $20 → $12 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 419.48% | RBC Capital | Gregory Renza56% | $12 → $10 | Maintains | Outperform | Get Alert |
| 04/24/2023 | Buy Now | 3.9% | B of A Securities | Tazeen Ahmad73% | $7 → $2 | Downgrade | Neutral → Underperform | Get Alert |
| 02/13/2023 | Buy Now | 523.38% | RBC Capital | Gregory Renza56% | $18 → $12 | Maintains | Outperform | Get Alert |
| 01/24/2023 | Buy Now | 159.74% | Morgan Stanley | Matthew Harrison54% | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 01/04/2023 | Buy Now | 938.96% | HC Wainwright & Co. | Robert Burns44% | $21 → $20 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 263.64% | Morgan Stanley | Matthew Harrison54% | $11 → $7 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 938.96% | RBC Capital | Gregory Renza56% | $25 → $20 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 263.64% | B of A Securities | Tazeen Ahmad73% | $14 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2022 | Buy Now | 159.74% | JP Morgan | Brian Cheng49% | → $5 | Initiates | → Overweight | Get Alert |
| 09/19/2022 | Buy Now | 990.91% | HC Wainwright & Co. | Robert Burns44% | $20 → $21 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | 471.43% | Morgan Stanley | Matthew Harrison54% | $17 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/22/2022 | Buy Now | 938.96% | HC Wainwright & Co. | Robert Burns44% | $44 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 1406.49% | RBC Capital | Gregory Renza56% | $30 → $29 | Maintains | Outperform | Get Alert |
| 07/11/2022 | Buy Now | 2185.71% | HC Wainwright & Co. | Robert Burns44% | $54 → $44 | Maintains | Buy | Get Alert |
FAQ
What is the target price for ADC Therapeutics (ADCT) stock?
The latest price target for ADC Therapeutics (NYSE:ADCT) was reported by RBC Capital on May 15, 2025. The analyst firm set a price target for $8.00 expecting ADCT to rise to within 12 months (a possible 315.58% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADC Therapeutics (ADCT)?
The latest analyst rating for ADC Therapeutics (NYSE:ADCT) was provided by RBC Capital, and ADC Therapeutics reiterated their outperform rating.
When was the last upgrade for ADC Therapeutics (ADCT)?
The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.
When was the last downgrade for ADC Therapeutics (ADCT)?
The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.
When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on May 15, 2025 so you should expect the next rating to be made available sometime around May 15, 2026.
Is the Analyst Rating ADC Therapeutics (ADCT) correct?
While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $8.00 to $8.00. The current price ADC Therapeutics (ADCT) is trading at is $1.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
